TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip

Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.

Analyst Commentary

Following the recent earnings report, analysts have provided updated perspectives on TG Therapeutics, contributing to the upward revision of price targets and highlighting both positive and cautionary factors for investors to consider.

• Bullish analysts underscore confidence in ongoing sales growth, specifically citing expectations for multi-year expansion in Briumvi U.S. revenues.
• Recent model updates reflect an improved margin outlook and support higher valuation levels compared to prior estimates.
• There is consensus that the company is well positioned to exceed $1 billion in product sales within the next few years, signaling strong execution potential.
• Some view the recent share price decline following earnings as a buying opportunity and emphasize optimism about the long-term growth trajectory.

• Cautious analysts remain mindful of execution risks as the company aims for ambitious multi-year sales targets.
• The sustainability of margin improvements will require continued operational discipline and monitoring over subsequent quarters.
• Post-earnings volatility in the stock raises concerns about investor sentiment and the potential impact of future earnings releases.

What's in the News

• TG Therapeutics raised its global revenue target for 2025 to approximately $600 million, an increase from the prior guidance of $585 million (Corporate Guidance: Raised).
• Enrollment has completed in the Phase 3 ENHANCE trial studying a new dosing schedule for BRIUMVI in relapsing forms of multiple sclerosis, further evaluating safety and efficacy (Product-Related Announcements).
• New six-year data from the ULTIMATE I & II Phase 3 trials of BRIUMVI were presented at ECTRIMS 2025, supporting the long-term safety and effectiveness of the therapy in RMS patients (Product-Related Announcements).
• TG Therapeutics commenced enrollment for a Phase 3 trial of subcutaneous BRIUMVI for patients with relapsing forms of multiple sclerosis (Product-Related Announcements).
• The company completed a share repurchase program, buying back 3.5 million shares for nearly $100 million, as authorized by its Board of Directors (Buyback Transaction Announcements).

Valuation Changes

• The discount rate has risen slightly from 6.89% to 7.09%, reflecting a modest increase in perceived risk or required return.
• Revenue growth has increased minimally from 37.75% to 37.82%, showing expectations for slightly stronger top-line expansion.
• Net profit margin has climbed from 28.00% to 32.93%, indicating a more optimistic view of profitability improvements.
• The future P/E has declined from 20.98x to 17.68x, suggesting that analysts now expect stronger future earnings relative to share price.
• Fair value remains unchanged at $44.29, despite the adjustments to growth and profitability assumptions.